Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $57.68 | $5,768.00 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 80,106 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 818 | $56.79 | $46,454.22 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 80,206 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $56.58 to $57.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 50 | $57.68 | $2,884.00 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,737 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,593 | $57.05 | $775,480.65 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,787 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $56.67 to $57.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,257 | $56.54 | $297,230.78 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661,380 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $55.67 to $56.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,957 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 487 | $57.01 | $27,763.87 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,024 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $56.94 to $57.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,847 | $55.98 | $215,355.06 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,511 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $55.54 to $56.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,013 | $57.06 | $286,041.78 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,656,318 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $56.80 to $57.43. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 19,015 | $55.94 | $1,063,699.10 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661,331 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $55.48 to $56.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:58 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-008744 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,680,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2019 Filed Feb 8, 2019 00:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 156,100 | $0.00 Strike: $57.33 | $0.00 |
DisclosureSEC source: 0001209191-19-008293 · doc4.xml · derivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,100 Underlying: Common Stock · 156,100 shares Expires 2029-02-05 F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 1, 2020, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 05, 2019 Filed Feb 8, 2019 00:51 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 93,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008293 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,670,027 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2020, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,276 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,390 | $52.59 | $73,100.10 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Family Partnership Disclosed balance after: 85,358 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $51.98 to $52.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 702 | $51.83 | $36,384.66 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 86,748 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $50.91 to $51.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,085 | $52.93 | $110,359.05 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,576,427 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $52.86 to $53.105. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,975 | $52.37 | $679,500.75 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,578,512 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $51.86 to $52.855. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stoc | 12,848 | $51.46 | $661,158.08 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591,487 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $50.86 to $51.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,595 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,550 | $52.42 | $186,091.00 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,594,016 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $52.33 to $52.58. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 26,450 | $51.93 | $1,373,548.50 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597,566 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $51.335 to $52.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-19-005246 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,624,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,912 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,914 Underlying: Common Stock · 20,912 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 25,600 | $45.05 | $1,153,280.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613,697 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $44.61 to $45.445. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stoc | 4,400 | $44.12 | $194,128.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,297 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $43.60 to $44.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 20,912 | $3.60 | $75,283.20 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,643,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,826 Underlying: Common Stock · 30,000 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $45.75 | $4,575.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,785 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,507 | $44.84 | $291,773.88 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,885 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $44.50 to $45.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,493 | $44.12 | $507,071.16 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629,392 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $43.50 to $44.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,900 | $43.08 | $512,652.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,640,885 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $42.50 to $43.475. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 30,000 | $3.60 | $108,000.00 |
DisclosureSEC source: 0001209191-19-002653 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,002 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,826 Underlying: Common Stock · 11,002 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,836 | $40.91 | $75,110.76 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 87,450 F2 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $40.50 to $41.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,227 | $41.29 | $380,982.83 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,622,785 F2 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $41.07 to $41.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,937 | $40.75 | $771,682.75 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632,012 F2 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $40.06 to $41.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 11,002 | $3.60 | $39,607.20 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,650,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 6,373 | $40.93 | $260,846.89 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,947 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| December 03, 2018 Filed Dec 7, 2018 01:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,287 | $43.93 | $100,467.91 |
DisclosureSEC source: 0001209191-18-061413 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646,320 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| November 21, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,828 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| November 21, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $39.47 | $36,233.46 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 89,286 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $39.10 to $39.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $39.47 | $745,983.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648,607 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $39.00 to $39.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,147 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $39.65 | $3,965.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 90,204 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 818 | $39.20 | $32,065.60 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 90,304 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $38.50 to $39.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 400 | $39.95 | $15,980.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,657,188 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $39.895 to $39.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.